SPECT/CT PROSTASCINT imaging guides prostate cancer therapy

11/4/2009 | Reuters

SPECT/CT images of PROSTASCINT, a monoclonal antibody attached to the radioisotope Indium-111 for specific targeting of prostate-specific membrane antigen, helped identify areas that needed increased doses of radioactive seeds in patients at risk for metastatic prostate cancer. The images also helped in evaluating for biochemical disease-free survival by showing the presence or absence of lymph node metastases.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC